Taysha Gene Therapies Q2 EPS $(0.13) Misses $(0.12) Estimate
Taysha Gene Therapies (NASDAQ: TSHA ) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.12) by 8.33 percent. This is a 44.44 percent decrease over losses of $(0.09) per share from the same period last year.